TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02937649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy using 48-Fr bougie
Description: After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy using standard care bougie
Description: After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
Study: NCT02743897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavyret
Description: Mavyret (glecaprevir 100 mg and pibrentasvir 40 mg) is taken by mouth for 8 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Study: NCT00371176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exposure therapy
Description: A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
Study: NCT03247881

Intervention type: OTHER
Group type: OTHER
Intervention: Nut Free Diet
Description: Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Added Mixed Nuts Diet
Description: Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
Study: NCT03743844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-focused psychoeducation group
Description: Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
Study: NCT00564291

Intervention type: OTHER
Intervention: Examination with an OCT device

Intervention type: OTHER
Intervention: Examination with an OCT device

Intervention type: OTHER
Intervention: Examination with an OCT device

Intervention type: OTHER
Intervention: Examination with an OCT device

Intervention type: OTHER
Intervention: Examination with an OCT device

Intervention type: OTHER
Intervention: Examination with an OCT device
Study: NCT00895934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV or subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV or subcutaneously (SC)
Study: NCT02534519

Intervention type: OTHER
Intervention: Whole Genome Sequencing (WGS)
Description: There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.

Intervention type: OTHER
Intervention: Whole Genome Sequencing (WGS)
Description: There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
Study: NCT00500253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: exhaled nitric oxide measurement
Description: exhaled nitric oxide measurement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchial hyperresponsiveness with methacholine (PC20M)
Description: bronchial hyperresponsiveness with methacholine (PC20M)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bronchial hyperresponsiveness with methacholine (PC20M)
Description: bronchial hyperresponsiveness with methacholine (PC20M)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: symptom score diary (according to 2007 GINA guidelines)
Description: symptom score diary (according to 2007 GINA guidelines)
Study: NCT01310582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study: NCT01227239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 40-60mg/m2/week intravenously on day 1, 8, 22 and 29.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total dose is 50.4Gy (1.8Gy X 28 fractions)
Study: NCT00915603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus 10mg PO daily continuously for all 28 days of a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
Study: NCT00371176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
Study: NCT00915603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO daily continuously for all 28 days of a cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
Study: NCT03585712

Intervention type: DRUG
Group type: OTHER
Intervention: Norgestrel 0.075 mg
Description: Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3

Intervention type: DRUG
Group type: OTHER
Intervention: Norgestrel 0.075 mg
Description: Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3
Study: NCT00371176

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Study: NCT04306393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Gas
Description: 80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio \>/= 300 for at least 24 hours consecutively.
Study: NCT01002248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine will be dosed as one 50 mg pill every day of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perifosine Placebo
Description: Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
Study: NCT03184129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trial group
Description: Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: control group
Description: Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
Study: NCT00594074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white wine
Description: 3.25 ounces of white wine twice a day with lunch and dinner
Study: NCT01420042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lemon flavoured cordial and Water for Injection
Study: NCT01288209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 100-mg capsule taken by mouth once daily for 12 or 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 100-mg capsule taken by mouth once daily for 12 or 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (PegIFNα-2a )
Description: PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (PegIFNα-2a )
Description: PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
Study: NCT01573949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
Study: NCT01882153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Training (PRT)
Description: The behaviorally-based intervention is a treatment model that uses the principles of Applied Behavior Analysis (Koegel, Openden, Fredeen, \& Koegel, 2006) to increase children's adaptive behaviors and decrease maladaptive behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE Therapy
Description: The developmentally based intervention is grounded in a development theory, that focuses on child-directed interactions with warm and caring individuals that aid in acquiring missed developmental and functional milestones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE and PRT Hybrid
Description: The hybrid based treatment has an eclectic approach that incorporates both systematic (behaviorally-based) and affect-based learning (developmentally-based)that focuses on increasing children's skill development (http://www.pacificautism.org).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE and PRT Hybrid
Description: The hybrid based treatment has an eclectic approach that incorporates both systematic (behaviorally-based) and affect-based learning (developmentally-based)that focuses on increasing children's skill development (http://www.pacificautism.org).
Study: NCT01461889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfuse plasma to High INR target
Description: Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfuse plasma to Low INR target
Description: Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
Study: NCT00583466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous blood injection
Description: Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be injected under the lesion to create submucosal cushion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPMC
Description: Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
Study: NCT00351377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate Sodium
Description: Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
Study: NCT00423813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem®
Description: two doses
Study: NCT02610530

Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy with Ileal Transposition
Description: Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.

Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy with Transit Bipartition
Description: Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.

Intervention type: OTHER
Intervention: Medical Treatment
Description: Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
Study: NCT01408719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Minimal beta-glucan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3g LMW beta-glucan
Description: 3grams beta-glucan
Study: NCT00312585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Study: NCT00731133

Intervention type: DRUG
Group type: OTHER
Intervention: Disulfiram
Description: 250 mg/day
Study: NCT00012064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
Study: NCT03809039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6345
Description: MT-6345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6345
Description: MT-6345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6345 Placebo
Description: MT-6345 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6345 Placebo
Description: MT-6345 Placebo
Study: NCT00967967

Intervention type: DRUG
Group type: OTHER
Intervention: Medication Mometasone furoate and desloratadine
Description: One month treatment with both drugs
Study: NCT03699189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate ANAIS
Description: ANAIS is a structured therapeutic education programme aimed at providing the patients with the necessary skills to manage their diabetes independently and confidently. The programme particularly promotes dietary freedom, in an intensive insulin regime, by enabling effective carbohydrate counting and accurate prandial insulin dose adjustment and avoiding hypoglycaemia.~ANAIS was organised as a five day (Monday to Friday), seven-hour, outpatient programme using principles of adult education, with explicit learning objectives, in a group setting.
Study: NCT04324216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D virtual reality and hands-on aromatherapy
Description: Participants will receive 8-session 3DVR aroma therapy activities. Each session was delivered over 2 hours once a week, and at each session, the participant received hands-on guidance for preparing an aromatherapy product that they could use for the next seven days.
Study: NCT04550819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraintestinal extended biliary stents
Description: The test group will be placed intraintestinal extended biliary stents in intrahepatic bile duct in ERCP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraintestinal extended biliary stents
Description: The test group will be placed intraintestinal extended biliary stents in intrahepatic bile duct in ERCP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ordinary plastic biliary stents
Description: The test group will be placed ordinary plastic biliary stents in intrahepatic bile duct in ERCP
Study: NCT01408719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5g LMW beta-glucan
Description: 5 grams beta-glucan

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3g HMW beta-glucan
Description: 3 grams of high molecular weight beta-glucan
Study: NCT04550819

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ordinary plastic biliary stents
Description: The test group will be placed ordinary plastic biliary stents in intrahepatic bile duct in ERCP
Study: NCT03334877

Intervention type: DIAGNOSTIC_TEST
Intervention: β -human chorionic gonadotropin
Description: Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.
Study: NCT02735304

Intervention type: OTHER
Group type: OTHER
Intervention: Impression intervention
Description: The 1st intervention will compare two clinical impression techniques The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment. The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Impression intervention
Description: The 1st intervention will compare two clinical impression techniques The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment. The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment.
Study: NCT01173900

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gardasil® HPV vaccine
Description: 0.5 ml given at 0, 2, 6 months

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gardasil® HPV vaccine
Description: 0.5 ml given at 0, 2, 6 months
Study: NCT03849703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Intervention #1
Description: Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the coparenting and then romantic relationship curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Intervention #2
Description: Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the romantic relationship and then coparenting curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Partial Intervention #1
Description: Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the romantic relationship curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Partial Intervention #2
Description: Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the coparenting curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.